Carisma Therapeutics

At Carisma we are focused on three principles of work to make engineered myeloid cell therapy a reality: ? Testing and validating our foundational scientific perspective ? Redefining manufacturing ? Fueling, amplifying and extending our platform’s capabilities through thoughtful partnerships Register for our upcoming webcast to learn about how these principles are guiding our latest efforts to leverage the CAR-Macrophage platform:?https://bit.ly/39dHRwm

Carisma Therapeutics is thrilled to be presenting two posters at the SITC 2024 conference in Houston! Join us on November 8, 2024, as we, alongside Moderna, share groundbreaking data on our anti-GPC3 in vivo CAR-M therapy for hepatocellular carcinoma. We'll also highlight our trial-in-progress poster for the Phase 1 study of anti-HER2 CAR-Monocytes targeting solid tumors. Looking forward to connecting with the immunotherapy community! #SITC2024 #Immunotherapy #CellTherapy #Oncology #Innovation #CancerResearch

Tune in today at 4:00 pm ET for Carisma Therapeutics President & Chief Executive Officer Steven Kelly presentation at the Chardan Genetic Medicines Conference. A link to the webcast is available on the investor section of our website: https://bit.ly/3TvbKNh

Don’t miss Carisma Therapeutics President & Chief Executive Officer Steven Kelly presentation today at the H.C. Wainwright Healthcare Conference at 1:30 pm ET. The webcast is available on the investor section of our website: https://lnkd.in/eyHna8cV

Tune in today at 12:50 pm ET, Carisma Therapeutics Chief Executive Officer Steven Kelly will participate in a fireside chat at the Baird Global Healthcare Conference: https://lnkd.in/eyHna8cV

Today, we announced the expansion of our collaboration with Moderna to develop two in vivo CAR-M therapies for autoimmune diseases. This builds on our preclinical success in oncology, advancing potential new treatments for patients. Learn more about the strategic collaboration which combines Carisma’s chimeric antigen receptor macrophage platform with Moderna’s mRNA and lipid nanoparticle technologies to generate and develop in vivo CAR-M therapeutics for autoimmune diseases: https://lnkd.in/e-EZnHhu #Immunotherapy #AutoimmuneDiseases #Biotech #CARMTherapies #Collaboration

This week, we will be presenting at the upcoming Baird Global Healthcare Conference and H.C. Wainwright Healthcare Conference. Read our press release for full details: https://lnkd.in/e5WdDcuN

Today we provided a business update and reported financial results for the second quarter 2024. For full details and results, read today’s press release: https://lnkd.in/epMcBFnQ

Tune in today at 10:55 am ET for Carisma Therapeutics Chief Scientific Officer Michael Klichinsky presentation at the Immuno-Oncology Summit 2024 in Philadelphia. Head to the event website for a full schedule of events and to register: 12th Annual Immuno-Oncology Summit | August 7-9, 2024 | Philadelphia, PA

We are excited to announce the addition of two distinguished leaders, Dr. Scott Friedman and Dr. Ira Tabas, to Carisma’s Scientific Advisory Board! ? Dr. Friedman and Dr. Tabas bring extensive expertise and pioneering contributions in liver fibrosis, which will be instrumental as Carisma continues its program to develop transformative treatments for patients. ? We extend our warm welcome to Dr. Scott Friedman and Dr. Ira Tabas! Read more in the press release here: https://lnkd.in/e37JqitW